Keywords: GLP-1, obesity, overweight, fractures, bone, pharmacotherapy Introduction GLP-1 RAs were first identified in the 1980s and received FDA approval in 2005 as anti-hyperglycemic agents for the treatment of diabetes (1)
Patients on dialysis or with end-stage renal disease should not receive GLP-1 agonists without nephrology oversight
The therapy cost guide helps budget for the full protocol, and the cost calculator can model scenarios with your specific supplier pricing
Care is personalized and includes medical guidance, follow-up visits, and support for nutrition, lifestyle, and underlying contributors such as sleep, mental health, stress, and gut health.
If you're considering retatrutide, the safest path is enrollment in a clinical trial where you'll receive pharmaceutical-grade medication with full medical supervision